Cervical Adenocarcinoma: A Still Under-investigated Malignancy
Anticancer Research · 2023
DOI: 10.21873/anticanres.16133 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anticancer Research, 2023. Verfasst von Sabina Pistolesi und 7 weiteren Autor:innen. Beteiligte Einrichtung: First Division of Pathology, Department of Laboratory Medicine, Pisa University Hospital, Pisa, Italy; s.pistolesi@ao-pisa.toscana.it. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Adenocarcinoma. Die Arbeit wurde bisher 3-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- First Division of Pathology, Department of Laboratory Medicine, Pisa University Hospital, Pisa, Italy; s.pistolesi@ao-pisa.toscana.it.
- First Division of Pathology, Department of Laboratory Medicine, Pisa University Hospital, Pisa, Italy.
- Division of Pathology, Department of Translational Research & New Technologies in Medicine & Surgery, University of Pisa, Pisa, Italy.
- Division of Gynaecology and Obstetrics, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Zitieren
APA
Pistolesi, S., Fanelli, G. N., Giudice, F., Garbini, F., Naccarato, A. G., Cosio, S., Caretto, M., & Gadducci, A. (2023). Cervical Adenocarcinoma: A Still Under-investigated Malignancy. Anticancer Research. https://doi.org/10.21873/anticanres.16133
Vancouver
Pistolesi S, Fanelli GN, Giudice F, Garbini F, Naccarato AG, Cosio S, et al. Cervical Adenocarcinoma: A Still Under-investigated Malignancy. Anticancer Research. 2023. doi:10.21873/anticanres.16133
BibTeX
@article{Pistolesi2023,
author = {Pistolesi, Sabina and Fanelli, Giuseppe Nicolò and Giudice, Francesco and Garbini, Francesca and Naccarato, Antonio Giuseppe and Cosio, Stefania and Caretto, Marta and Gadducci, Angiolo},
title = {Cervical Adenocarcinoma: A Still Under-investigated Malignancy},
journal = {Anticancer Research},
year = {2023},
doi = {10.21873/anticanres.16133}
}
EUVIMED